A motor function measure scale for neuromuscular …

1 A motor function measure scale for neuromuscular and validation studyCarole Be rarda,*, Christine Payanb, Isabelle Hodgkinsona, Jacques Fermanianc,The MFM Collaborative Study GroupaDepartment of Paediatric Rehabilitation, l Escale, Centre Hospitalier Lyon-Sud, 69495 Pierre Be nite, FrancebAFM, Institute of Myology, Ho pital Pitie -Salpe`trie`re, Paris, FrancecDepartment of Biostatistics, Ho pital Necker, Paris, FranceReceived 19 November 2004; received in revised form 7 March 2005; accepted 15 March 2005 AbstractA new scale for motor function measurement has been developed for neuromuscular diseases.

2 The validation study included 303 patients,aged 6 62 years. Seventy-two patients had Duchenne muscular dystrophy, 32 Becker muscular dystrophy, 30 limb-girdle musculardystrophy, 39 facio-scapulo-humeral dystrophy, 29 myotonic dystrophy, 21 congenital myopathy, 10 congenital muscular dystrophy, 35spinal muscular atrophy and 35 hereditary neuropathy. The scale comprised 32 items, in three dimensions: standing position and transfers,axial and proximal motor function , distal motor function . Agreement coefficients for inter-rater reliability were excellent ( ) fornine items, good ( ) for 20 items and moderate ( ) for three items.

3 High correlations were found between the totalscore and other scores: Vignos ( ) and Brooke ( ) grades, Functional Independence measure ( ), the global severity ofdisability evaluated with visual analog scales by physicians ( ) and physiotherapists ( ). This scale is reliable, does not requireany special equipment and is well-accepted by patients. Its sensitivity to change is being assessed to permit its use in clinical trials ofneuromuscular Elsevier All rights : neuromuscular disease ; motor function ; Metrology; scale ; validation ; Clinical trials1.

4 IntroductionIn neuromuscular diseases, identification of new geno-types and hope for gene therapy have obliged scientists andclinicians to collaborate in order to classify phenotypesmore precisely and to link them to specific genetic of motor deficit, and in particular measurementof muscle force by muscle testing or instrumental measures,is the most frequently used evaluation[1,2]. However, thismuscle testing does not reflect the subject s functionalabilities. These depend on the heterogeneity of the muscledefect, the muscular compensations and the limitations ofthe tests for the measurement of motor function havebeen proposed: the Functional motor scale for spinalmuscular atrophy (SMA)[3]; the ALS score[4], the TuftsQuantitative neuromuscular Exam[5]and the AmyotrophicLateral Sclerosis Functional Rating scale [6]for amyo-trophic lateral sclerosis.

5 The Hughes Functional Score[7]forGuillain-Barre syndrome and the Hammersmith MotorAbility Score[8]for Duchenne muscular dystrophy(DMD). Some tests focus on the function of one part ofthe body: the Zupan Functional Test[9]or the BrookeUpper Extremity scale [1]for the upper limbs and theVignos Lower Extremity scale for the lower limbs[10];other tests specifically address a single medical questionsuch as the Diagnostic motor Performance Test[11]forestablishing the differential diagnosis between myopathyand neuropathy.

6 Some have not been validated: Timed tasks[1]and others are non-specific such as the Jebsen HandFunction Test[12], or have not been adapted or validated forneuromuscular diseases, like the Gross motor FunctionMeasure which has been validated for cerebral palsy[13].At the moment, there is no well validated test which is easyto administer and which has been adapted for the objectiveNeuromuscular Disorders 15 (2005) 463 $ - see front matterq2005 Elsevier All rights *Corresponding author. Fax:C33 4 78 86 32 (C.)

7 Be rard).evaluation of motor function in the most frequent neuro-muscular diseases[14].In this paper, we describe the results of a validation studyof the motor function measure (MFM), a new scale toassess severity and disease progression of neuromusculardiseases. This scale is designed for use by physiotherapistsor rehabilitation physicians in their daily clinical practice. Itcould also be useful for clinical Material and methodsThe study was approved by the Medical EthicalCommittee of the Academic Medical Center Lyon A(France) and the Ethics Committee of Lausanne University(Switzerland).

8 Adult patients and parents of affectedchildren gave written informed consent prior to were personally asked to sign a consent construction of the Initial versionPhysical therapists, occupational therapists and rehabi-litation physicians who had experience in the managementof patients with neuromuscular diseases participated in thecreation of the scale . Initially 75 scale items were selectedbased on (i) various published motor function scales,mainly the Gross motor function measure , (ii) theexperience of the investigators and (iii) a pilot testingwith patients and parents.

9 The development of the MFMscale began in 1998, with items written in French andtranslated in English. This draft initial version was sentwith a demonstration video to 115 groups in Europe andNorth America. Forty-seven groups provided expertiseconcerning the selection of the diseases to which the scalecould be appropriate, the age groups of patients and in theselection and scoring of the items. Based on criticismsand suggestions, the MFM study group created a firstversion including 51 items.

10 Each item was rated on a 5-point scale (0/No movement 4/Completely normalmovement). First validation studyThe French 51-item version was evaluated between May2000 and March 2001 in 16 centers in France and one centerin Switzerland. The participating centers included hospitalgroups, physical therapy centers, motor handicap centers,and a residential facility for handicapped people. Three-hundred and seventy-six patients with a suspected orconfirmed diagnosis of neuromuscular disease , excludingmyasthenia and myositis, aged 6 60 years, were tested by18 trained physiotherapists[15].